cancers-logo

Journal Browser

Journal Browser

Gastrointestinal Tumors: Prevention, Screening and Predictive Analytics

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: 1 June 2026 | Viewed by 645

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA
Interests: cancer control; precision medicine; drug-drug interactions; dynamic treatment regimes; casual inference; comparative effectiveness research; design and analysis of clinical trials
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Cancer Control and Prevention, Department of Internal Medicine, College of Medicine and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
Interests: breast cancer screening; cervical cancer screening; colorectal cancer screening; health disparities; cancer prevention; cancer survivorship; rural disparities; implementation science; HPV vaccination; behavioral intervention research
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Rutgers–Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA
Interests: gastroenterology; liver disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gastrointestinal (GI) tumors remain one of the leading causes of cancer morbidity and mortality worldwide. Progress in prevention, screening, and predictive analytics is crucial for shifting diagnosis to an earlier stage, tailoring risk, and reducing disparities.

This Special Issue invites original research articles and reviews that advance the prevention, risk assessment, or early detection of GI and hepatobiliary malignancies. We welcome studies on population and genetic risk models, biomarkers (including blood- and stool-based assays, ctDNA/methylation signatures, proteomics, and the microbiome), imaging and radiomics approaches for early detection, comparative effectiveness of screening strategies and pathways, chemoprevention strategies, agents, and trials, and AI/ML models integrating clinical, laboratory, endoscopic, and imaging data. Submissions emphasizing methodological rigor, transparent reporting, calibration, external validation/transportability, decision-analytic evaluation, and implementation science (including uptake, adherence, and equity) are particularly encouraged. Additionally, analyses of feasibility and cost-effectiveness in diverse health systems are also encouraged. To maintain a focus on early detection and risk, submissions centered primarily on therapeutic interventions or survivorship without a clear prevention, screening, or prediction component are outside the scope of this Special Issue.

We look forward to contributions that can be translated into practical applications and policies to meaningfully improve outcomes across the GI cancer control continuum.

You may choose our Joint Special Issue in Current Oncology.

Dr. Mohamed I. Elsaid
Prof. Dr. Electra D. Paskett
Prof. Dr. Vinod Rustgi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal and hepatobiliary cancers
  • prevention and screening
  • chemoprevention
  • risk stratification
  • biomarkers and liquid biopsy (ctDNA)
  • imaging and radiomics
  • predictive analytics and machine learning
  • causal inference
  • population-based studies
  • implementation science and health equity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 3907 KB  
Article
The Burden of Liver Cancer in Selected East Asian Countries (1990–2021) and Projections up to 2036: A Systematic Analysis of the Global Burden of Disease Study 2021
by Tianhao Guo, Yu Zhao, Linyu Xu, Yumo Yuan, Yifan Hui, Tingting Zhou, Wenjian Zhu, Liu Li, Weixing Shen, Haibo Cheng and Xiaoyu Wu
Cancers 2026, 18(8), 1272; https://doi.org/10.3390/cancers18081272 - 16 Apr 2026
Viewed by 344
Abstract
Background: Liver cancer remains a persistent global health challenge due to its high occurrence and fatality rates, critically impacting health outcomes and quality of life. The disease burden in East Asia, considering China, Japan, South Korea, and Mongolia, is among the highest [...] Read more.
Background: Liver cancer remains a persistent global health challenge due to its high occurrence and fatality rates, critically impacting health outcomes and quality of life. The disease burden in East Asia, considering China, Japan, South Korea, and Mongolia, is among the highest globally. This study aims to examine the patterns and trends of liver cancer in selected East Asian countries from 1990 to 2021. Methods: This study employed data from the Global Burden of Disease Study 2021 pertaining to key burden metrics—prevalence, incidence, mortality, years of life lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs)—for selected East Asian countries from 1990 to 2021. Furthermore, the epidemiological trends and patterns were analyzed using decomposition analysis, Joinpoint regression, and age–period–cohort methods. Projections of the cancer burden through 2036 were generated using the Bayesian age–period–cohort model. Results: For all key indicators (incidence, prevalence, mortality, YLDs, YLLs, and DALYs), China had the highest values in both 1990 and 2021. The highest age-standardized rates for incidence (ASIR), mortality (ASMR), prevalence (ASPR), YLDs, YLLs, and DALYs (ASDR) were recorded in Mongolia. For all measured indicators of disease burden, the peak rates in each of the selected East Asian nations were consistently concentrated in the population aged 50 and above. Mongolia is forecasted to maintain the top-ranking ASIR values among the selected East Asian nations considered up to 2036. Conclusions: Over the past three decades, liver cancer has imposed a heavy disease burden on all selected East Asian nations, with rates being notably higher in the elderly population. These insights will provide policy-makers with evidence to guide public health strategies for disease prevention. Full article
Show Figures

Figure 1

Back to TopTop